Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{164407,
        author = {Rutuja S. Devkar and Shivani V. Mohite and Dhanushree M. Gosavi and Ravi P. Barkde},
        title = {Aplastic Anemia.},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {10},
        number = {12},
        pages = {668-674},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=164407},
        abstract = {Aplastic anemia (AA) is an uncommon, potentially fatal, and diverse blood condition. The aplastic anemia pathogenesis. The ratio of men to women is roughly 1:1. While aplastic anemia affects people of all ages, there is a slight peak in incidence that is seen in children. Aplastic anemia can be explained by either intrinsic abnormality of marrow progenitors or extrinsic immune-mediated suppression of hematopoietic stem cells. An unsuccessful bone marrow transplant can cure the underlying illness. A traditional treatment for marrow failure syndromes is androgen therapy.
Patients with aplastic anemia have extremely high blood levels of thrombopoietin, but in the presence of interferon-γ, eltrombopag may evade a block to receptor engagement. The most frequent side effects of aplastic anemia are infections, bleeding, or lymph proliferative disorders.
},
        keywords = {Aplastic Anemia, Progenitors.},
        month = {},
        }